Understanding how melanoma tumors behave differently in various organs
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance
This study is looking at how melanoma tumors that spread to different parts of the body react to treatments like BRAF inhibitors and immunotherapy, using samples from patients who have had warm autopsies, to help find better ways to treat people with advanced melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10828407 on NIH RePORTER |
What this research studies
This research investigates how melanoma tumors that spread to different organs respond differently to treatments like BRAF inhibitors and immunotherapy. By analyzing multiple tumor samples from patients who have undergone warm autopsies, the study aims to understand the biological differences and adaptations of these tumors in relation to their specific organ environments. The researchers will perform detailed genomic and transcriptomic analyses to uncover the mechanisms behind therapeutic resistance in melanoma. This comprehensive approach seeks to provide insights that could lead to more effective treatment strategies for patients with metastatic melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic melanoma who have undergone treatment and are willing to participate in postmortem analysis.
Not a fit: Patients with early-stage melanoma or those who have not received treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with metastatic melanoma by identifying specific tumor characteristics that influence therapy responses.
How similar studies have performed: Previous research has shown that understanding tumor heterogeneity can lead to significant advancements in cancer treatment, suggesting that this approach has the potential for success.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Hugo, Willy — University of California Los Angeles
- Study coordinator: Hugo, Willy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.